This segment focuses on the research, development, and clinical trials of long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS). Lyra Therapeutics utilizes its proprietary XTreo technology platform to deliver medication directly to the affected tissues, providing sustained release with a single administration. The primary product candidates are LYR-210, currently in Phase II clinical trials, and LYR-220, targeting CRS patients with and without nasal polyps. The company's R&D efforts are centered on improving the efficacy and safety of these implants, with a focus on achieving statistically significant results in clinical trials. The patient impact is significant, as CRS significantly impacts quality of life. Market positioning is based on providing a novel treatment option for a large patient population with unmet medical needs. Future opportunities include expanding the application of the XTreo platform to other ENT diseases and securing regulatory approvals for commercialization. Partnerships and collaborations are key to advancing clinical trials and commercialization efforts.